

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)  
10903 New Hampshire Avenue, Silver Spring, Maryland  
February 26, 2020

**MEETING ROSTER**

---

**DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Lauren Tesh Hotaki, PharmD, BCPS, BCIDP**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Massimo Cristofanilli, MD, FACP**

Associate Director of Translational Research and  
Precision Medicine  
Robert H. Lurie Comprehensive Cancer Center  
Chicago, Illinois

**Jorge A. Garcia, MD**

Former Associate Professor of Medicine  
Cleveland Clinic Lerner College of Medicine  
Case Western Reserve University  
Cleveland, Ohio

**Susan Halabi, PhD**

Professor of Biostatistics and Bioinformatics  
Duke University Medical Center  
Durham, North Carolina

**Christian S. Hinrichs, MD**

Investigator & Lasker Clinical Research Scholar  
Experimental Transplantation and Immunology  
Branch  
National Cancer Institute (NCI)  
National Institutes of Health (NIH)  
Bethesda, Maryland

**Philip Hoffman, MD**

*(Chairperson)*  
Professor of Medicine  
The University of Chicago  
Section of Hematology/Oncology  
Department of Medicine  
Chicago, Illinois

**Heidi D. Klepin, MD, MS**

Professor of Internal Medicine  
Section of Hematology and Oncology  
Wake Forest University Health Sciences  
Winston Salem, North Carolina

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)**

**Jonathan D. Cheng, MD**

*(Industry Representative)*  
Vice President and Oncology Therapeutic Area Head  
Merck Research Laboratories, Oncology Clinical  
Research  
North Wales, Pennsylvania

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
February 26, 2020

**MEETING ROSTER (cont.)**

---

---

**TEMPORARY MEMBERS (Voting)**

**John Deeken, MD**

*(Afternoon Session Only)*  
President, Inova Schar Cancer Institute  
Fairfax, Virginia

**Randy W. Hawkins, MD**

*(Acting Consumer Representative)*  
Department of Internal Medicine  
Internal Medicine/Pulmonary & Critical Care  
Charles R. Drew University of Medicine and Science  
Los Angeles, California

**Maha Hussain, MD, FACP, FASCO**

*(Morning Session Only)*  
Genevieve Teuton Professor of Medicine  
Division of Hematology/Oncology  
Deputy Director  
Robert H. Lurie Comprehensive Cancer Center  
Northwestern University Feinberg School of  
Medicine  
Chicago, Illinois

**Terrence “Terry” Kungel, MBA**

*(Patient Representative; Morning Session Only)*  
Woolwich, Maine

**Danil V. Makarov, MD, MHS**

*(Morning Session Only)*  
Associate Professor of Urology, Population Health,  
and Health Policy  
New York University School of Medicine  
New York, New York

**Shakun Malik, MD**

*(Afternoon Session Only)*  
Head, Thoracic and Head & Neck Cancer  
Therapeutics  
Clinical Investigations Branch,  
Cancer Therapeutics Evaluation Program  
Division of Cancer Treatment and Diagnosis  
NCI, NIH  
Bethesda, Maryland

**Tracy G. Matson**

*(Patient Representative; Afternoon Session Only)*  
Little Rock, Arkansas

**Brian I. Rini, MD**

*(Morning Session Only)*  
Chief, Clinical Trials  
Vanderbilt-Ingram Cancer Center  
Ingram Professor of Medicine  
Vanderbilt University  
Nashville, Tennessee

**Howard Sandler, MD, MS, FASTRO, FASCO**

*(Morning Session Only)*  
Professor and Chair, Department of Radiation  
Oncology  
Cedars-Sinai Medical Center  
Los Angeles, California

**Mohammad Minhaj Siddiqui, MD, FACS**

*(Morning Session Only)*  
Associate Professor of Surgery  
Director, Urologic Oncology  
University of Maryland School of Medicine  
Chief of Urology  
Veterans Affairs Maryland Healthcare System  
Baltimore, Maryland

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
February 26, 2020

**MEETING ROSTER (cont.)**

---

---

**TEMPORARY MEMBERS (Voting) (cont.)**

**Daniel Y. Song, MD**

*(Morning Session Only)*

Co-Director, Prostate Cancer Multidisciplinary Clinic  
Professor of Radiation Oncology and Molecular  
Radiation Sciences  
Johns Hopkins Hospital  
Baltimore, Maryland

**Eva Szabo, MD**

*(Afternoon Session Only)*

Chief, Lung & Upper Aerodigestive Cancer  
Research Group, Division of Cancer Prevention  
NCI, NIH  
Bethesda, Maryland

**Patrick C. Walsh, MD**

*(Morning Session Only)*

University Distinguished Service Professor Emeritus  
James Buchanan Brady Urological Institute  
Johns Hopkins Hospital  
Baltimore, Maryland

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

Director, Oncology Center of Excellence (OCE)  
Acting Director, Office of Oncologic Diseases (OOD)  
Office of New Drugs (OND), CDER, FDA

**Paul Kluetz, MD**

*(Morning Session Only)*

Deputy Center Director, OCE  
Supervisory Associate Director for Clinical  
Oncology (Acting)  
OOD, OND, CDER, FDA

**Julia Beaver, MD**

*(Morning Session Only)*

Director, Division of Oncology 1 (DO1)  
OOD, OND, CDER, FDA

**Chana Weinstock, MD**

*(Morning Session Only)*

Team Leader, Genitourinary Cancers Team  
DO1, OOD, OND, CDER, FDA

**Sundeep Agrawal, MD**

*(Morning Session Only)*

Clinical Reviewer, Genitourinary Cancers Team  
DO1, OOD, OND, CDER, FDA

**Xin (Cindy) Gao, PhD**

*(Morning Session Only)*

Biostatistics Reviewer  
Division of Biometrics V (DBV)  
Office of Biostatistics (OB)  
Office of Translational Sciences (OTS), CDER, FDA

**Harpreet Singh, MD**

*(Afternoon session only)*

Acting Director  
Division of Oncology 2 (DO2)  
OOD, OND, CDER, FDA

**Erin Larkins, MD**

*(Afternoon session only)*

Cross-Discipline Team Leader  
Thoracic and Head & Neck Cancers Team  
DO2, OOD, OND, CDER, FDA

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
February 26, 2020

**MEETING ROSTER (cont.)**

---

---

**FDA PARTICIPANTS (Non-Voting) (cont.)**

**Barbara Scepura, MS, CRNP**

*(Afternoon session only)*

Clinical Reviewer

Thoracic and Head & Neck Cancers Team

DO2, OOD, OND, CDER, FDA

**Xiaoxue Li, PhD**

*(Afternoon session only)*

Statistics Reviewer

DBV, OB, OTS, CDER, FDA